9-cis-UAB-30

9-cis-UAB-30 (also known as UAB-30 or 9cUAB30) is a synthetic, conformationally restricted analog of 9-cis-retinoic acid that acts as a selective agonist of the retinoid X receptor (RXR). Developed by the University of Alabama at Birmingham (UAB) in collaboration with the National Cancer Institute (NCI), 9-cis-UAB-30 is designed to selectively activate RXR homodimers and RXR/RAR heterodimers without binding to retinoic acid receptors (RARs) directly. This selectivity allows it to induce cell differentiation, inhibit cell proliferation, and promote apoptosis in cancer cells while avoiding the toxicities typically associated with pan-retinoid agonists, such as hypertriglyceridemia and hypothyroidism. 9-cis-UAB-30 has been investigated in clinical trials for the chemoprevention of breast cancer and non-melanoma skin cancer.

Other names

(2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid(9Z)-UAB-30retinoid 9cUAB30retinoid9cUAB30retinoid-9cUAB30